Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Depression 3 Breast Neoplasms 2 Anxiety Disorders 2 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Hospice 1 Hematopoietic and Lymphoid System Neoplasm 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gynecologic Cancer 1 Gastrointestinal Neoplasms 1 Emotional Regulation 1 Colonic Neoplasms 1 Advanced Cancer 1 Acute Pain 1

Interventions

Surveys and Questionnaires 7 Standard of Care 5 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Interviews as Topic 4 Paclitaxel 3 olaparib 2 Vorinostat 2 Olanzapine 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Dasatinib 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olanzapine-fluoxetine combination 1 nimotuzumab 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × Psychotherapy × Clear all

NCT05398484 2025-12-04

Psilocybin Therapy in Advanced Cancer

NYU Langone Health

Phase 2/3 Recruiting

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡